| abstract |
This invention provides a TauT-peptide vaccine for cancer immunotherapy and, more particularly, a method of preventing tumor carcinogenesis comprising the steps of administering to an animal and/or human subject having a precancerous precursor of various cancers, including, but not limited to, lymphoma, sarcoma, carcinoma, thymoma, and leukemia. This invention also provides a pharmaceutical preparation comprising a TauT-peptide vaccine (prophylactic and therapeutic) to prevent, suppress or inhibit spontaneous tumorigenesis in vivo. The present invention provides a safe and effective method for suppressing or inhibiting spontaneous tumorigenesis and is particularly useful for preventing subjects having elevated risk of developing p53 gene mutation associated cancers. |